Clinical Efficacy of Convalescent Plasma for Treatment of COVID-19 Infections: Results of a Multicenter Clinical Study

Since Dec. 2019 the new coronavirus (SARS-CoV-2) has infected millions and claimed life of several hundred thousand worldwide. However, so far no approved vaccine or drug therapy is available for treatment of virus infection. Convalescent plasma has been considered a potential modality for COVID-19 infection. One hundred eighty-nine COVID-19 positive patients including 115 patients in plasma therapy group and 74 patients in control group, registered in the hospitals with confirmed COVID-19 infection, entered this multi-center clinical study. Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. This clinical study provides strong evidence to support the efficacy of convalescent plasma therapy in COVID-19 patients and recommends this treatment for management of these patients. Clinical efficacy, immediate availability and potential cost effectiveness could be considered as main advantages of convalescent plasma therapy.

Citing Articles

Alteration of Lung Physiology with the Administration of Convalescent Plasma in ARDS Patients Intubated with COVID-19 Pneumonia.

Presti T, Nathanson B, Schlecht H, Steingrub J, DiNino E Brown J Hosp Med. 2025; 2(1):39621.

PMID: 40046554 PMC: 11878892. DOI: 10.56305/001c.39621.

The Progress and Challenges of Convalescent Plasma Therapy for Coronavirus Disease 2019.

Shi M, Zhang C, Wang F Infect Dis Immun. 2024; 1(1):52-58.

PMID: 38630075 PMC: 8057313. DOI: 10.1097/01.ID9.0000733568.58627.47.

Efficacy and Safety of Treatment with Plasma from COVID-19-Recovered Individuals.

Terada M, Saito S, Kutsuna S, Kinoshita-Iwamoto N, Togano T, Hangaishi A Life (Basel). 2023; 13(11).

PMID: 38004324 PMC: 10671928. DOI: 10.3390/life13112184.

Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis.

Senefeld J, Gorman E, Johnson P, Moir M, Klassen S, Carter R Mayo Clin Proc Innov Qual Outcomes. 2023; 7(5):499-513.

PMID: 37859995 PMC: 10582279. DOI: 10.1016/j.mayocpiqo.2023.09.001.

Drug target of natural products and COVID-19: how far has science progressed?.

Raman K, Rajagopal K, Ramesh B, Nallasivan P, Raja M, Jupudi S Ann Med Surg (Lond). 2023; 85(6):2731-2742.

PMID: 37363478 PMC: 10289732. DOI: 10.1097/MS9.0000000000000703.

References

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Bloch E, Shoham S, Casadevall A, Sachais B, Shaz B, Winters J . Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020; 130(6):2757-2765. PMC: 7259988. DOI: 10.1172/JCI138745. View

Joyner M, Wright R, Fairweather D, Senefeld J, Bruno K, Klassen S . Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest. 2020; 130(9):4791-4797. PMC: 7456238. DOI: 10.1172/JCI140200. View

Cheng Y, Wong R, Soo Y, Wong W, Lee C, Ng M . Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2004; 24(1):44-6. PMC: 7088355. DOI: 10.1007/s10096-004-1271-9. View

Fleming A, Raabe V . Current studies of convalescent plasma therapy for COVID-19 may underestimate risk of antibody-dependent enhancement. J Clin Virol. 2020; 127:104388. PMC: 7187833. DOI: 10.1016/j.jcv.2020.104388. View

Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo F, Chong M . Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020; 323(16):1612-1614. PMC: 7082763. DOI: 10.1001/jama.2020.4326. View

Tiberghien P, de Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y . Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?. Vox Sang. 2020; 115(6):488-494. DOI: 10.1111/vox.12926. View

Soo Y, Cheng Y, Wong R, Hui D, Lee C, Tsang K . Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004; 10(7):676-8. PMC: 7129386. DOI: 10.1111/j.1469-0691.2004.00956.x. View

Arabi Y, Hajeer A, Luke T, Raviprakash K, Balkhy H, Johani S . Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia. Emerg Infect Dis. 2016; 22(9):1554-61. PMC: 4994343. DOI: 10.3201/eid2209.151164. View

10.

Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F . Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. J Med Virol. 2020; 92(10):1890-1901. PMC: 7262027. DOI: 10.1002/jmv.25882. View

11.

Abdi M . Coronavirus disease 2019 (COVID-19) outbreak in Iran: Actions and problems. Infect Control Hosp Epidemiol. 2020; 41(6):754-755. PMC: 7137533. DOI: 10.1017/ice.2020.86. View

12.

Langhi Junior D, de Santis G, Bordin J . COVID-19 convalescent plasma transfusion. Hematol Transfus Cell Ther. 2020; 42(2):113-115. PMC: 7164882. DOI: 10.1016/j.htct.2020.04.003. View

13.

Pan F, Ye T, Sun P, Gui S, Liang B, Li L . Time Course of Lung Changes at Chest CT during Recovery from Coronavirus Disease 2019 (COVID-19). Radiology. 2020; 295(3):715-721. PMC: 7233367. DOI: 10.1148/radiol.2020200370. View

14.

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

15.

Sullivan H, Roback J . Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. Transfus Med Rev. 2020; 34(3):145-150. PMC: 7179481. DOI: 10.1016/j.tmrv.2020.04.001. View

16.

Cheraghali A, Abolghasemi H, Eshghi P . Management of COVID-19 Virus Infection by Convalescent Plasma. Iran J Allergy Asthma Immunol. 2020; 19(S1):3-6. DOI: 10.18502/ijaai.v19i(s1.r1).2847. View

17.

Luke T, Kilbane E, Jackson J, Hoffman S . Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?. Ann Intern Med. 2006; 145(8):599-609. DOI: 10.7326/0003-4819-145-8-200610170-00139. View

18.

Ahn J, Sohn Y, Lee S, Cho Y, Hyun J, Baek Y . Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020; 35(14):e149. PMC: 7152526. DOI: 10.3346/jkms.2020.35.e149. View

19.

Casadevall A, Pirofski L . The convalescent sera option for containing COVID-19. J Clin Invest. 2020; 130(4):1545-1548. PMC: 7108922. DOI: 10.1172/JCI138003. View

20.

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View